Literature DB >> 1994693

Antibody responses to four Haemophilus influenzae type b conjugate vaccines.

H Käyhty1, J Eskola, H Peltola, P R Rönnberg, E Kela, V Karanko, L Saarinen.   

Abstract

Serum antibody responses to four Haemophilus influenzae type b capsular polysaccharide-protein conjugate vaccines (PRP-D, HbOC, C7p, and PRP-T) were studied and compared in 175 infants, 85 adults and 140 2-year-old children. Antibodies to the H influenzae type b polysaccharide vaccines were determined with a Farr-type radioimmunoassay. The infants received two doses of vaccine at the ages of 4 and 6 months. After the first dose of vaccine, the geometric mean antibody concentration measured at the age of 6 months was 0.09 to 0.10 mg/L, only marginally higher than that measured before immunization in all infants who had received PRP-D, HbOC, or C7p but increased to 0.82 mg/L in those who had received PRP-T. One month after the second dose, the geometric mean antibody concentration was increased in all vaccine groups. No significant differences were noted between recipients of HbOC, C7p, or PRP-T (geometric mean antibody concentrations, 4.32, 3.10, and 6.10 mg/L, respectively), whereas the PRP-D recipients had a significantly lower geometric mean antibody concentration (0.63 mg/L). In contrast, PRP-D, HbOC, C7p, and PRP-T were all highly immunogenic in adults, with no differences noted among them. The 2-year-old children also responded to one dose of these vaccines with a high antibody concentration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1994693     DOI: 10.1001/archpedi.1991.02160020117030

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  14 in total

1.  B and T cell immunity in patients with lysinuric protein intolerance.

Authors:  M Lukkarinen; K Parto; O Ruuskanen; O Vainio; H Käyhty; R M Olander; O Simell
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

2.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

Review 3.  Cost of treatment and prevention of Haemophilus influenzae type b disease. An international perspective.

Authors:  D A Clements
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

Review 4.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

5.  Phase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers.

Authors:  Gilda Toraño; Maria E Toledo; Alberto Baly; Violeta Fernandez-Santana; Francisco Rodriguez; Yunia Alvarez; Teresita Serrano; Alexis Musachio; Ibis Hernandez; Eugenio Hardy; Arlene Rodríguez; Hector Hernandez; Aristides Aguilar; Raydel Sánchez; Manuel Diaz; Verena Muzio; Jorgelina Dfana; Maria C Rodríguez; Lazaro Heynngnezz; Vicente Verez-Bencomo
Journal:  Clin Vaccine Immunol       Date:  2006-09

6.  Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

Authors:  A Soininen; G van den Dobbelsteen; L Oomen; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

7.  Statement on Haemophilus influenzae type b conjugate vaccines for use in infants and children.

Authors: 
Journal:  CMAJ       Date:  1993-01-15       Impact factor: 8.262

Review 8.  Haemophilus influenzae type b conjugate vaccines.

Authors:  Dominic F Kelly; E Richard Moxon; Andrew J Pollard
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

9.  Defective antibody response to Hemophilus influenzae type b immunization in children receiving peritoneal dialysis.

Authors:  B A Fivush; B Case; B A Warady; H Lederman
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

Review 10.  Bacterial meningitis: mechanisms of disease and therapy.

Authors:  R F Kornelisse; R de Groot; H J Neijens
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.